Healthy vs Unhealthy Obesity: Mehanistic Insights and Effects of Time-Restricted Eating
NCT ID: NCT05136313
Last Updated: 2024-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
53 participants
INTERVENTIONAL
2022-06-24
2024-01-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Time-Restricted Eating, Exercise and Cardiometabolic Health in Obesity
NCT05897073
Metabolic Phenotyping for Personalized Obesity Therapy
NCT06874270
Effects of Intermittent Fasting on Fatty Liver Disease
NCT04795973
Nutrigenetic Intervention on Blood Lipid Markers and Body Composition of Adults With Overweight and Obesity
NCT05210023
Natural Course of Initially Metabolic Healthy Obese Individuals (Healthy Obesity)?
NCT06799897
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will recruit young (20-22y-old) males with obesity (Body Mass Index≥30) and classify them as MHO or MUO (≤1 or ≥3 metabolic syndrome risk factors, respectively). A 16-week, 8h TRE intervention will be conducted in MHO vs. MUO subgroups, to assess and compare the anthropometric, metabolic, endocrine, inflammatory and peripheral blood mononuclear cell (PBMC) mechanistic/signaling response.
The investigators expect to advance the understanding of cellular mechanisms implicated in MHO and MUO, including potential therapeutic targets. Ultimately, the investigators expect to find relevant opportunities for intervention to prevent the serious cardiometabolic consequences of obesity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MHO
metabolically healthy obese subjects undergoing TRE
Time-restricted eating
16 weeks of TRE consisting of an 8-hour eating window.
MUO
metabolically unhealthy obese subjects undergoing TRE
Time-restricted eating
16 weeks of TRE consisting of an 8-hour eating window.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Time-restricted eating
16 weeks of TRE consisting of an 8-hour eating window.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI≥30
* Own and use a Smartphone with Apple iOS or Android OS
* Baseline eating period ≥ 13 h per day.
Exclusion Criteria
* Shift workers
* Known inflammatory and/or rheumatologic disease
* History of cardiovascular event
* Thyroid or adrenal disease, malignancy or diabetes
* History of eating disorder.
* Special diet (e.g., celiac disease),or any other disease or treatment that may interfere with the study.
18 Years
25 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Agencia Nacional de Investigación y Desarrollo
OTHER
Universidad Católica del Maule
OTHER
Instituto de Nutrición y Tecnología de los Alimentos
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mariana Cifuentes
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mariana Cifuentes, PhD
Role: PRINCIPAL_INVESTIGATOR
Universidad de Chile INTA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
INTA, Universidad de Chile
Santiago, RM, Chile
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1211477
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.